Atara Biotherapeutics, Inc. (NASDAQ:ATRA – Get Rating) SVP Amar Murugan sold 3,612 shares of the business’s stock in a transaction on Wednesday, November 16th. The shares were sold at an average price of $4.49, for a total transaction of $16,217.88. Following the completion of the transaction, the senior vice president now directly owns 127,586 shares of the company’s stock, valued at approximately $572,861.14. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Atara Biotherapeutics Price Performance
ATRA stock opened at $4.27 on Monday. The stock has a market capitalization of $405.13 million, a P/E ratio of -1.73 and a beta of 1.02. Atara Biotherapeutics, Inc. has a fifty-two week low of $2.83 and a fifty-two week high of $18.85. The business has a 50-day moving average of $4.24 and a 200-day moving average of $4.86.
Hedge Funds Weigh In On Atara Biotherapeutics
A number of large investors have recently bought and sold shares of the company. Balyasny Asset Management LLC raised its holdings in shares of Atara Biotherapeutics by 213.3% in the third quarter. Balyasny Asset Management LLC now owns 58,472 shares of the biotechnology company’s stock valued at $221,000 after purchasing an additional 39,806 shares during the last quarter. BNP Paribas Arbitrage SNC boosted its holdings in Atara Biotherapeutics by 637.5% during the third quarter. BNP Paribas Arbitrage SNC now owns 198,267 shares of the biotechnology company’s stock worth $749,000 after purchasing an additional 171,382 shares during the last quarter. Alliancebernstein L.P. grew its position in Atara Biotherapeutics by 43.4% in the third quarter. Alliancebernstein L.P. now owns 107,040 shares of the biotechnology company’s stock valued at $405,000 after purchasing an additional 32,400 shares in the last quarter. State Street Corp increased its stake in Atara Biotherapeutics by 30.1% in the 3rd quarter. State Street Corp now owns 8,097,353 shares of the biotechnology company’s stock valued at $30,608,000 after buying an additional 1,875,667 shares during the last quarter. Finally, Public Employees Retirement System of Ohio lifted its position in Atara Biotherapeutics by 83.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 255,611 shares of the biotechnology company’s stock worth $966,000 after buying an additional 116,134 shares in the last quarter.
Analysts Set New Price Targets
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is an allogeneic T-cell immunotherapy company, which pioneers the development of transformative therapies for patients with serious diseases including solid tumors, hematologic cancers, and autoimmune diseases. also delivers off-the-shelf treatments to patients with high unmet medical need.
- Get a free copy of the StockNews.com research report on Atara Biotherapeutics (ATRA)
- Is GameStop Stock Setting Up for Another Short Squeeze?
- Here’s Why SoFi Technologies Stock is Cheap at These Levels
- Warren Buffet Bought Taiwan Semiconductor Stock, Should You?
- MarketBeat: Week in Review 11/14 – 11/18
- Target’s Double Bottom Might Have Just Been Confirmed
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.